Referências
Principais artigos
Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003 Jul 7;64(7):1535-50. Resumo
Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J. 2002 Dec;95(12):1411-8. Resumo
Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999 Nov;10(11):2446-53.Texto completo Resumo
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Texto completo Resumo
Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019 Jun;34(3):171-354. Resumo
Artigos de referência
1. Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003 Jul 7;64(7):1535-50. Resumo
2. Sethi S, Lewin M, Lopez L, et al. Linear anti-glomerular basement membrane IgG but no glomerular disease: Goodpasture's syndrome restricted to the lung. Nephrol Dial Transplant. 2007 Apr;22(4):1233-3. Resumo
3. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J. 2002 Dec;95(12):1411-8. Resumo
4. Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999 Nov;10(11):2446-53.Texto completo Resumo
5. Niles JL, Bottinger SP, Saurina GT, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996 Feb 26;156(4):440-5. Resumo
6. Li FK, Tse KC, Lam MF, et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology. 2004 Apr;9(2):100-4. Resumo
7. Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983 Dec 17;2(8364):1390-3. Resumo
8. Herody M, Duvic C, Noel LH, et al. Cigarette smoking and other inhaled toxins in anti-GBM disease. Contrib Nephrol. 2000;130:94-102. Resumo
9. Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int. 1999 Nov;56(5):1638-54. Resumo
10. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967 Dec 1;126(6):989-1004. Resumo
11. Ryan JJ, Reynolds J, Norgan VA, et al. Expression and characterization of the recombinant rat alpha 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 2001 Feb;16(2):253-61.Texto completo Resumo
12. Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol. 2006 May;17(5):1253-63.Texto completo Resumo
13. Wu J, Hicks J, Borillo J, et al. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest. 2002 Feb;109(4):517-24.Texto completo Resumo
14. Cairns LS, Phelps RG, Bowie L, et al. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type IV collagen in Goodpasture's disease. J Am Soc Nephrol. 2003 Nov;14(11):2801-12.Texto completo Resumo
15. Serisier DJ, Wong RC, Armstrong JG. Alveolar haemorrhage in anti-glomerular basement membrane disease without detectable antibodies by conventional assays. Thorax. 2006 Jul;61(7):636-9.Texto completo Resumo
16. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med. 1992;21(2):141-53. Resumo
17. Lauwerys R, Bernard A, Viau C, et al. Kidney disorders and hematotoxicity from organic solvent exposure. Scand J Work Environ Health. 1985;11 Suppl 1:83-90.Texto completo Resumo
18. Anonide A, Rebora A. What lichen planus patients die of: a retrospective study. Int J Dermatol. 1989 Oct;28(8):524-6. Resumo
19. Boardman EA, Sohail S, Yadavilli R. Goodpasture's disease with late presentation of renal abnormality and anti-GBM autoantibody. BMJ Case Rep. 2017 Mar 17;2017. Resumo
20. Wilson CB, Smith RC. Goodpasture's syndrome associated with influenza A2 virus infection. Ann Intern Med. 1972 Jan;76(1):91-4.
21. Prendecki M, Clarke C, Cairns T, et al. Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int. 2020 Sep;98(3):780-81.Texto completo
22. Phelps R, Winston JA, Wynn D, et al. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Mult Scler. 2019 Aug;25(9):1273-88.Texto completo Resumo
23. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med. 2008 Aug 14;359(7):768-9.Texto completo
24. Javaugue V, Watson MJ, Fervenza FC, et al. Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor. Kidney Int Rep. 2022 Aug;7(8):1913-16.Texto completo
25. Al-Chalabi S, Wu HHL, Chinnadurai R, et al. Etanercept-induced anti-glomerular basement membrane Disease. Case Rep Nephrol Dial. 2021 Sep-Dec;11(3):292-300.Texto completo Resumo
26. Browne G, Brown PA, Tomson CR, et al. Retransplantation in alport post-transplant anti-GBM disease. Kidney Int. 2004 Feb;65(2):675-81.Texto completo Resumo
27. Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int. 1992 Jul;42(1):179-87.Texto completo Resumo
28. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986 May;45(5):359-66. Resumo
29. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Texto completo Resumo
30. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019 Jun;34(3):171-354. Resumo
31. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-ii90.Texto completo Resumo
32. Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 Jun 5;134(11):1033-42. Resumo
33. Shah MK. Outcomes in patients with Goodpasture's syndrome and hydrocarbon exposure. Ren Fail. 2002 Sep;24(5):545-55. Resumo
34. Hu W, Liu Z, Ji D, et al. Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients. J Nephrol. 2006 May-Jun;19(3):312-7. Resumo
35. Bygren P, Freiburghaus C, Lindholm T, et al. Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet. 1985 Dec 7;2(8467):1295-6. Resumo
36. Soveri I, Mölne J, Uhlin F, et al. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019 Nov;96(5):1234-38.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal